first
two
invit
articl
review
develop
nucleosideanalogu
antivir
drug
written
target
audienc
virologist
nonchemist
well
chemist
may
familiar
field
rather
provid
simpl
chronolog
account
examin
attempt
explain
thought
process
advanc
synthet
chemistri
lesson
learn
antivir
test
led
molecul
move
forward
eventu
approv
human
therapi
other
discard
present
paper
focus
earli
rel
simplist
chang
made
nucleosid
scaffold
begin
modif
nucleosid
sugar
arac
arabinosederiv
nucleosid
analogu
futur
paper
review
recent
develop
focus
especi
complex
modif
particularli
involv
multipl
chang
nucleosid
scaffold
hope
articl
help
virologist
other
outsid
field
medicin
chemistri
understand
certain
drug
success
develop
major
candid
compound
encount
barrier
due
lowyield
synthet
rout
toxic
problem
led
abandon
nucleosid
nucleotid
analogu
long
rich
histori
field
medicin
chemistri
perigaud
et
al
de
clercq
de
clercq
de
clercq
field
de
clercq
de
clercq
de
clercq
natur
occur
nucleosid
repres
uniqu
start
point
drug
design
due
involv
numer
critic
biolog
process
well
fact
serv
essenti
build
block
dna
rna
synthesi
modif
structur
design
andor
refin
base
key
interact
identifi
bind
site
target
enzym
current
nucleosidetid
analogu
market
approv
use
treat
virus
cancer
parasit
well
bacteri
fungal
infect
mani
current
clinic
preclin
trial
perigaud
et
al
de
clercq
field
de
clercq
jordheim
et
al
niu
tan
de
clercq
li
lapponi
et
al
maffioli
et
al
wataya
et
al
isono
andriol
nucleosid
compos
sugar
moieti
nucleobas
wherea
nucleotid
nucleosid
also
contain
least
one
phosphat
phosphatelik
group
numer
natur
occur
nucleosid
found
natur
five
common
dna
rna
biolog
process
includ
adenosin
guanosin
cytidin
thymidin
uridin
fig
result
even
small
chang
structur
profound
effect
ideal
nucleosidetid
analogu
mimic
structur
natur
nucleosid
recogn
cellular
viral
enzym
howev
due
modif
structur
lead
disrupt
andor
termin
replic
biolog
process
de
clercq
de
clercq
neyt
sinc
enzym
recognit
depend
mani
factor
includ
shape
electron
hydrogen
bond
interact
possibl
design
analogu
activ
particular
biolog
target
particularli
mechan
action
known
inform
bind
site
avail
contempl
potenti
modif
nucleosid
scaffold
sever
differ
site
consid
sugar
moieti
aromat
heterocycl
base
glycosid
bond
connect
sugar
heterocycl
base
andor
phosphat
group
nucleotid
fig
perigaud
et
al
jordheim
et
al
modif
made
simpli
ad
substitu
group
heterocycl
base
sugar
replac
atom
either
group
move
atom
differ
posit
combin
approach
perigaud
et
al
jordheim
et
al
similar
modif
also
made
phosphat
group
nucleotid
analogu
roy
et
al
de
clercq
pertusati
et
al
even
posit
glycosid
bond
shift
exampl
anoth
carbon
howev
latter
tradit
less
common
modif
agrofoglio
et
al
marquez
lim
modif
also
done
combin
therebi
allow
larg
amount
divers
nucleosid
structur
function
earli
exampl
nucleosid
analogu
featur
modif
sugar
analogu
greatli
increas
knowledg
normal
nucleosid
interact
also
interact
could
exploit
medicin
purpos
modif
includ
ad
remov
substitu
furanos
sugar
ring
chang
ring
size
even
remov
furanos
oxygen
creat
entir
new
class
nucleosid
first
nucleosid
discov
medicin
properti
arabinos
ara
analogu
conform
hydroxyl
group
posit
invert
rather
found
ribos
nucleosid
fig
feeney
bergmann
burk
first
two
ara
nucleosid
natur
product
includ
spongothymidin
spongouridin
isol
caribbean
spong
tethya
crypta
earli
feeney
sipkema
et
al
neither
spongothymidin
spongouridin
ever
becam
use
drug
discoveri
led
synthesi
variou
arabinos
deriv
nucleosid
analogu
spongoadenosin
araa
spongocytidin
arac
synthes
fig
bergmann
burk
sipkema
et
al
bauer
hamann
et
al
walwick
et
al
lee
et
al
arac
cytarabin
approv
clinic
use
consid
essenti
medicin
world
health
organ
due
potent
activ
mani
cancer
includ
nonhodgkin
lymphoma
importantli
mani
leukemia
myeloid
leukemia
acut
lymphat
leukemia
chronic
myelogen
leukemia
rees
schiller
schilski
et
al
bodey
et
al
hiddemann
momparl
rudnick
et
al
herzig
et
al
arac
still
current
use
primarili
anticanc
treatment
use
antivir
therapi
also
explor
earli
unfortun
advers
effect
observ
high
dose
arac
antihsv
treatment
includ
myelotox
gastrointestin
toxic
thu
arac
never
pursu
antivir
drug
stentoft
lauter
et
al
hwang
et
al
araa
vidarabin
first
approv
fda
use
sever
virus
includ
herp
simplex
viru
well
herp
zoster
viru
afflict
mani
aid
patient
field
de
clercq
bauer
hamann
et
al
de
clercq
suzuki
et
al
lee
et
al
vidarabin
longer
use
due
toxic
issu
well
discoveri
potent
safer
compound
acyclovir
today
wide
prescrib
hsv
hamann
et
al
research
becam
awar
uniqu
properti
fluorin
impart
nucleosid
analogu
pankiewicz
watanab
pankiewicz
fluorin
often
use
isoster
replac
sinc
similar
size
hydrogen
also
similar
electroneg
hydroxyl
group
found
ribos
nucleosid
fluorin
found
extens
use
sugar
base
modif
latter
discuss
later
exampl
earli
studi
reveal
fluorin
greatli
influenc
conform
sugar
also
known
sugar
pucker
saenger
fluorin
electroneg
element
presenc
lock
sugar
specif
conform
turn
one
factor
affect
recognit
differ
enzym
ikeda
et
al
wojtowiczrajchel
exampl
enzym
dna
polymeras
revers
transcriptas
prefer
north
conform
also
known
kinas
gener
prefer
south
conform
fig
saenger
furthermor
found
presenc
fluorin
serv
increas
stabil
neighbor
bond
bohm
et
al
kirk
park
et
al
observ
also
led
site
potenti
modif
nucleosidetid
drug
design
includ
chang
heterocycl
base
glycosid
bond
sugar
moieti
phosphat
group
fig
exampl
ara
nucleosid
configur
found
arabinos
sugar
rather
configur
typic
ribos
nucleosid
discoveri
presenc
fluorin
sugar
decreas
nucleosid
suscept
enzymat
cleavag
glycosid
bonda
biolog
process
inactiv
nucleosid
drug
wojtowiczrajchel
park
et
al
gudmundsson
et
al
result
observ
fluorin
becom
common
modif
drug
design
one
first
exampl
explor
effect
fluorin
sugar
watanab
et
al
synthes
seri
nucleosid
fluorin
includ
analogu
given
activ
previous
note
ara
nucleosid
fig
pankiewicz
watanab
pankiewicz
prove
activ
analogu
howev
neither
analogu
prove
particularli
potent
fairli
toxic
pankiewicz
watanab
pankiewicz
year
later
eli
lilli
develop
first
exampl
nucleosid
gemin
substitu
becam
known
gemcitabin
gemzar
hertel
et
al
de
sousa
cavalcant
monteiro
brown
et
al
brown
et
al
analogu
groundbreak
discoveri
instal
two
ident
substitu
h
carbon
previous
tri
nucleosid
molecul
matter
mani
question
result
two
fluorin
would
overal
conform
sugar
logic
would
suggest
two
oppos
dipol
would
cancel
lead
chang
sugar
pucker
howev
later
shown
two
fluorin
pull
ring
carbon
plane
rather
north
south
confirm
importantli
potent
activ
gemcitabin
number
cancer
strike
hertel
et
al
de
sousa
cavalcant
monteiro
huang
et
al
oettl
et
al
gemcitabin
still
use
today
breast
ovarian
pancreat
bladder
nonsmal
cell
lung
cancer
de
sousa
cavalcant
monteiro
oettl
bergman
et
al
slusarczyk
et
al
bastiancich
et
al
due
initi
success
nucleosid
analogu
scientist
also
explor
modif
carbon
first
modifi
nucleosid
includ
analogu
fig
mikhailov
et
al
initi
sar
studi
found
serv
potent
anticanc
agent
numer
human
leukemia
carcinoma
cell
line
ic
valu
franchetti
et
al
cappellacci
et
al
analysi
found
shift
methyl
posit
anoth
posit
sugar
ring
associ
decreas
activ
thu
highlight
import
moieti
cappellacci
et
al
similarli
studi
found
adenosin
nucleobas
activ
analogu
human
myelogen
leukemia
cell
human
colon
carcinoma
cell
line
antiprolif
activ
found
nucleobas
cappellacci
et
al
test
abil
analogu
potenti
therapeut
osolodkin
group
studi
cytidin
tickborn
enceph
viru
howev
none
analogu
demonstr
potent
antivir
activ
orlov
et
al
due
lack
antivir
activ
well
develop
potent
anticanc
agent
analogu
extens
pursu
sinc
known
nucleosid
analogu
incorpor
grow
nucleic
acid
chain
via
templat
chain
incom
nucleotid
research
specul
nucleotid
miss
altern
function
group
present
posit
incorpor
occur
extens
grow
dna
chain
would
halt
de
clercq
neyt
deval
et
al
deval
hypothesi
led
mani
research
pursu
type
modif
therebi
introduc
new
class
nucleosid
analogu
design
chain
termin
analogu
signal
begin
new
era
nucleosid
drug
design
first
exampl
chain
termin
approach
nucleosid
dideoxycytidin
ddc
zalcitabin
dideoxyinosin
ddi
didanosin
fda
approv
nucleosid
revers
transcriptas
inhibitor
human
immunodefici
viru
hiv
fig
de
clercq
veal
et
al
mitsuya
broder
horwitz
et
al
plunkett
cohen
analogu
exampl
nucleosid
analogu
fluorin
configur
configur
gemcitabin
exampl
nucleosid
analogu
methyl
carbon
sugar
ring
configur
configur
quickli
follow
azt
zidovudin
demonstr
increas
activ
hiv
compar
previou
dideoxi
analogu
ic
compar
ddi
ddc
hostetl
et
al
shirasaka
et
al
horwitz
et
al
interestingli
three
compound
origin
pursu
anticanc
agent
howev
hiv
quickli
rose
forefront
emerg
diseas
research
found
three
quit
effect
hiv
martin
et
al
addit
dideoxynucleosid
also
use
sanger
sequenc
method
mid
rapid
method
determin
dna
sequenc
dna
polymeras
sanger
coulson
sanger
et
al
unfortun
number
problem
aros
azt
ddi
ddc
exampl
shown
ddi
acidlabil
thu
larg
buffer
tablet
necessari
neutral
stomach
ph
ensur
effect
deliveri
compound
martin
et
al
led
unwant
side
effect
includ
pancreat
peripher
neuropathi
well
overal
poor
patient
complianc
martin
et
al
fortun
year
initi
approv
enter
coat
small
capsul
form
ddi
develop
greatli
increas
patient
complianc
well
decreas
previous
describ
side
effect
martin
et
al
similarli
ddc
also
associ
numer
advers
effect
seriou
pain
peripher
neuropathi
occur
patient
treat
ddc
longer
week
martin
et
al
reason
well
poor
efficaci
ddc
longer
wide
use
azt
also
suffer
variou
side
effect
problem
toxic
serious
develop
viral
resist
boyer
et
al
kerr
anderson
richman
et
al
common
mechan
develop
resist
mutat
one
residu
revers
transcriptas
bind
site
larder
kemp
huang
et
al
meyer
et
al
gu
et
al
zhang
et
al
lead
drug
either
bind
least
less
effect
bind
problem
resist
welldocu
three
therapi
thu
research
consid
combin
therapi
ie
use
two
nucleosid
rather
standard
monotherapi
larder
kemp
meng
et
al
larder
et
al
st
clair
et
al
collier
et
al
research
ration
could
target
replic
pathway
hiv
two
differ
drug
would
increas
chanc
stop
develop
resist
sinc
shut
one
step
pathway
two
differ
mechan
two
differ
step
even
two
differ
drug
target
step
would
greatli
reduc
chanc
mutant
strain
gain
domin
meng
et
al
larder
et
al
collier
et
al
moreov
one
drug
work
mutant
strain
drug
vice
versa
would
exponenti
increas
chanc
effect
meng
et
al
larder
et
al
collier
et
al
mascolini
today
combin
therapi
consid
essenti
day
concern
would
lead
develop
even
seriou
mutat
resist
entir
class
drug
given
limit
amount
drug
avail
use
fear
would
lead
lack
drug
left
tri
mascolini
mascolini
rapid
emerg
resist
azt
ddc
field
focus
explor
addit
modif
sugar
posit
boyer
et
al
de
clercq
sarafiano
et
al
liotta
painter
result
effort
find
new
better
chain
termin
vigor
pursu
ultim
led
discoveri
numer
analogu
still
use
today
includ
stavudin
lamivudin
emtricitabin
ftc
fig
martin
et
al
baba
et
al
soudeyn
et
al
schinazi
et
al
horwitz
et
al
saag
like
ddi
ddc
stavudin
also
lack
moieti
also
introduc
unsatur
sugar
moieti
via
doubl
bond
carbon
turn
made
sugar
nearli
planar
due
increas
rigid
molecul
choi
et
al
interestingli
lamivudin
emtricitabin
also
exampl
l
nucleosid
mirror
imag
enantiom
natur
occur
nucleosid
discuss
later
review
also
featur
sulfur
atom
instead
carbon
sugar
ring
liotta
painter
vasconcelo
et
al
sinc
natur
nucleosid
nucleosid
long
thought
unnatur
enantiom
nonsuperimpos
mirror
imag
would
recogn
biolog
system
prove
case
ultim
approv
use
hiv
hepat
b
viru
hbv
demonstr
low
level
toxic
diminish
side
effect
fig
exampl
nucleosid
act
oblig
chain
termin
due
lack
incom
nucleotid
coupl
thu
chain
elong
termin
fig
exampl
second
gener
oblig
nucleosid
chain
termin
kl
seleyradtk
mk
yate
antivir
research
compar
aforement
chain
termin
includ
azt
de
clercq
liotta
painter
vasconcelo
et
al
doong
et
al
lamivudin
emtricitabin
featur
oxathiolan
sugar
research
found
could
also
replac
sulfur
atom
oxygen
atom
yield
dioxolan
sugar
led
develop
antihiv
analogu
dioxolan
cytidin
correspond
dioxolan
guanosin
fig
kim
et
al
kim
et
al
like
oxathiolan
sugar
analogu
dioxolan
analogu
chain
termin
due
lack
group
structur
uniqu
deoxynucleosid
demonstr
potent
antihiv
activ
ec
valu
pbm
cell
respect
cytidin
analogu
display
greater
cytotox
guanosin
analogu
kim
et
al
kim
et
al
studi
found
lenantiom
dioxolan
cytidin
analogu
troxacitabin
bch
demonstr
activ
variou
cancer
includ
renal
cell
carcinoma
leukemia
prostat
fig
kadhim
et
al
grove
et
al
gile
et
al
grove
cheng
siu
et
al
rabbani
et
al
furthermor
troxacitabin
also
demonstr
potent
activ
hbv
hiv
thu
point
import
analogu
kim
et
al
use
atom
replac
sugar
moieti
exemplifi
lamivudin
emtricitabin
first
exampl
type
modif
unusu
nucleosid
synthes
sheali
clayton
featur
cyclopentyl
ring
place
furanos
sugar
moieti
fig
sheali
clayton
analogu
later
name
aristeromycin
ari
subsequ
isol
streptomyc
citrocolour
found
potent
antivir
properti
virus
measl
parainfluenza
vaccinia
viru
vesicular
stomat
de
clercq
de
clercq
et
al
rawal
et
al
similarli
close
relat
structur
analogu
first
isol
ampullariella
regulari
hayashi
et
al
later
synthes
name
neplanocin
npca
similar
ari
npca
also
featur
cyclopentyl
ring
place
furanos
sugar
howev
ncpa
cyclopentyl
ring
possess
doubl
bond
carbon
fig
rawal
et
al
hayashi
et
al
hayashi
et
al
npca
ari
highli
activ
howev
also
quit
toxic
triphosph
form
close
mimick
atp
thu
lead
misincorpor
disrupt
mani
import
biolog
system
de
clercq
de
clercq
et
al
rawal
et
al
hayashi
et
al
wolf
borchardt
although
toxic
two
kept
use
medicin
carbocycl
scaffold
still
quit
attract
research
carbocycl
nucleosid
possess
sever
advantag
increas
lipophil
cell
permeabl
importantli
glycosid
bond
longer
unstabl
hemiamin
ether
affect
glycosid
hydrolas
thu
also
led
increas
stabil
agrofoglio
et
al
marquez
lim
stoeckler
et
al
comin
marquez
unfortun
carbocycl
nucleosid
hand
except
less
activ
correspond
ribos
nucleosid
marquez
lim
marquez
marquez
et
al
compar
sugar
pucker
natur
nucleosid
carbocycl
nucleosid
thymidin
carbathymidin
found
loss
furanos
oxygen
carbocycl
nucleosid
significantli
decreas
stereoelectron
effect
also
elimin
anomer
effect
well
decreas
import
gauch
interact
furan
oxygen
hydroxyl
group
marquez
marquez
et
al
boyer
et
al
mahler
et
al
mention
previous
interact
typic
influenc
sugar
either
north
south
conform
commonli
equilibrium
two
marquez
marquez
et
al
loss
interact
carbocycl
analogu
result
sugar
confirm
differ
greatli
standard
north
south
conform
thu
could
explain
decreas
activ
seen
carbocycl
deriv
marquez
marquez
et
al
boyer
et
al
et
al
recent
studi
howev
shown
alter
truncat
ch
oh
group
addit
endocycl
doubl
bond
carbocycl
scaffold
found
entecavir
could
increas
interact
andor
group
nucleosid
pharmacophor
thu
potenti
increas
biolog
activ
marquez
marquez
et
al
led
number
group
pursu
novel
carbocycl
analogu
see
increas
stabil
would
inde
improv
overal
antivir
properti
neplanocin
aristeromycin
unabl
use
drug
due
toxic
triphosph
form
focu
turn
design
carbocycl
analogu
could
phosphoryl
posit
one
pivot
exampl
replac
ch
oh
group
simpl
methyl
group
led
dramat
increas
activ
vaccinia
viru
well
vesicular
stomat
viru
fig
marquez
siddiqi
et
al
anoth
approach
prove
advantag
develop
analogu
schneller
et
al
group
remov
result
direct
connect
cyclopentyl
ring
patil
et
al
da
schneller
seley
et
al
seley
et
al
seley
et
al
seley
et
al
seley
et
al
hegd
et
al
hegd
et
al
barnard
et
al
surprisingli
despit
presenc
hydroxyl
group
phosphoryl
occur
sinc
shorten
bond
posit
hydroxyl
group
correctli
recogn
cellular
viral
kinas
patil
et
al
take
one
step
borchardt
schneller
seleyradtk
other
complet
remov
group
lead
truncat
ari
npca
analogu
hasob
et
al
zimmermann
et
al
seley
et
al
truncat
fig
earli
carbocycl
nucleosid
featur
ccn
glycosid
bond
stabl
compar
correspond
hemiacet
bond
found
natur
sugar
nucleosid
prove
extrem
fruit
retain
similar
activ
ari
npca
analogu
howev
associ
toxic
observ
zimmermann
et
al
zimmermann
et
al
seley
et
al
one
import
find
carbocycl
analogu
prove
potent
inhibitor
sadenosyllhomocystein
hydrolas
sahas
enzym
key
mani
biolog
methyl
marquez
lim
de
clercq
et
al
wolf
borchardt
marquez
wang
et
al
sahas
enzymat
target
avail
carbocycl
analogu
mani
carbocycl
compound
also
found
effect
polymeras
inhibitor
price
et
al
matyugina
et
al
one
exampl
carbovir
resembl
sugar
structur
doubl
bond
carbon
howev
carbovir
possess
cyclopentyl
ring
instead
furanos
ring
seen
well
guanin
nucleobas
instead
thymin
nucleobas
found
fig
vinc
et
al
carter
et
al
highli
strateg
unsatur
cyclopentyl
ring
increas
rigid
analogu
lack
furanos
oxygen
lead
increas
stabil
glycosid
bond
carbovir
vinc
et
al
carter
et
al
parker
et
al
carbovir
demonstr
abil
potent
antihiv
therapeut
cytotox
low
solubl
poor
oral
bioavail
limit
use
clinic
applic
yeom
et
al
order
allevi
issu
studi
carbovir
led
develop
abacavir
carbocycl
analogu
uniqu
modif
exocycl
amin
group
posit
nucleobas
fig
cyclopropyl
group
act
prodrug
moieti
abacavir
anabol
abacavir
cyclopropyl
group
undergo
deamin
vivo
yield
carbovir
faletto
et
al
tisdal
et
al
yuen
et
al
carbovir
convert
subsequ
variou
cellular
kinas
give
bioactiv
carbovir
vinc
et
al
dalug
et
al
faletto
et
al
sinc
abacavir
convert
activ
form
carbovir
vivo
also
act
potent
therapeut
abacavir
typic
administ
nucleosid
analogu
part
combin
therapi
demonstr
abil
overcom
bioavail
limit
associ
carbovir
tisdal
et
al
harrigan
et
al
one
import
exampl
carbocycl
nucleosid
entecavir
possess
group
introduc
highli
uniqu
exocycl
doubl
bond
place
furanos
oxygen
fig
bisacchi
et
al
wilber
et
al
entecavir
fda
approv
drug
treat
hiv
hbv
bisacchi
et
al
wilber
et
al
tang
et
al
interestingli
presenc
exocycl
doubl
bond
critic
increas
bind
affin
fit
hydrophob
pocket
hbv
polymeras
increas
efficaci
entecavir
hbv
tang
et
al
rawal
et
al
initi
howev
part
rational
overal
design
exocycl
doubl
bond
mere
chosen
increas
rigid
nucleosid
prevent
sugar
ring
flip
north
south
conform
well
maxim
distanc
orient
nucleobas
tang
et
al
langley
et
al
interestingli
entecavir
one
rare
exampl
ration
although
might
consid
irrat
design
nucleosid
fig
anoth
carbocycl
nucleosid
lobucavir
garner
much
attent
due
potent
antivir
activ
hbv
hsv
marquez
hayashi
et
al
norbeck
et
al
lobucavir
possess
cyclobutyl
sugar
ie
fourmemb
ring
resembl
natur
occur
oxetanocin
g
isol
bacteria
later
demonstr
antivir
activ
hiv
fig
marquez
time
research
bristol
myer
squibb
includ
lead
chemist
project
robert
zahler
look
design
someth
would
occupi
space
lobucavir
uniqu
carbocycl
cyclobutyl
nucleosid
structur
similar
natur
occur
oxetanocin
also
possess
four
member
sugar
ring
bisacchi
et
al
hayashi
et
al
specif
want
nucleosid
mimic
orient
nucleobas
well
distanc
guanin
base
fig
wilber
et
al
zahler
felt
strongli
two
factor
key
lobucavir
potent
activ
sinc
comput
chemistri
earli
stage
chemist
reli
physic
model
thu
zahler
ration
nt
matter
middl
kept
base
group
posit
correct
distanc
right
spatial
orient
wilber
et
al
specif
know
sugar
ring
prone
flip
conform
could
subsequ
abolish
activ
knew
would
import
hold
sugar
ring
rigid
enough
flip
occur
wilber
et
al
tang
et
al
langley
et
al
addit
sinc
ring
flip
would
impact
orient
heterocycl
base
either
anti
syn
conform
would
also
impact
recognit
mimick
specif
distanc
heterocycl
fig
exampl
second
gener
carbocycl
nucleosid
remov
gener
truncat
nucleosid
fig
structur
oblig
chain
termin
carbovir
nucleosid
featur
unsatur
sugar
ring
base
could
potenti
achiev
hold
base
prefer
conform
zahler
tri
number
approach
ultim
conceiv
cyclopentyl
ring
wherein
exocycl
doubl
bond
replac
furanos
oxygen
bisacchi
et
al
wilber
et
al
tang
et
al
would
rigidifi
ring
enough
avoid
ring
flip
also
predict
would
hold
nucleobas
oh
group
correct
orient
distanc
bisacchi
et
al
wilber
et
al
turn
overlap
lobucavir
quit
remark
entecavir
still
repres
one
best
wide
prescrib
antihbv
drug
market
langley
et
al
notabl
also
shown
particularli
effect
hiv
hbv
coinfect
patient
mcmahon
et
al
et
al
introduc
briefli
natur
occur
oxetanocin
possess
fourmemb
sugar
ring
oxetanocin
adenosin
mimic
possess
sugar
ring
found
activ
hiv
well
marquez
groaz
et
al
oxetanocin
g
correspond
guanosin
mimic
prove
effect
hiv
fig
marquez
interestingli
carbocycl
deriv
oxetanocin
carbaoxetanocin
oxetanocin
g
carbaoxetanocin
g
lobucavir
also
display
high
antivir
activ
numer
virus
includ
human
cytomegaloviru
hcmv
varicella
zoster
viru
fig
marquez
hayashi
et
al
norbeck
et
al
de
clercq
et
al
sekiyama
et
al
initi
studi
great
success
entecavir
well
oxetanocin
lobucavir
clear
ring
size
could
play
import
role
recognit
activ
one
ring
size
cyclopropyl
nucleosid
introduc
extrem
rigid
sugar
scaffold
howev
exhibit
moder
antivir
activ
hsv
hiv
sekiyama
et
al
ashton
et
al
qiu
et
al
aihong
joon
later
zemlicka
et
al
develop
zisom
purin
pyrimidin
synadenol
synguanol
demonstr
potent
activ
hcmv
ic
epsteinbarr
viru
ic
fig
qiu
et
al
baldanti
et
al
contrast
herdewijn
et
al
develop
numer
sixmemb
ring
nucleosid
includ
cyclohexenyl
hexos
nucleosid
analogu
shown
fig
wang
et
al
cyclohexenyl
analogu
pursu
two
primari
reasonscyclohexen
bioisoster
satur
furanos
ring
cyclohexenyl
analogu
resist
glycosid
hydrolysi
due
chang
glycosid
bond
hemiamin
ether
previous
discuss
wang
et
al
barral
et
al
herdewijn
de
clercq
wang
herdewijn
studi
demonstr
enantiom
one
particular
cyclohexenyl
nucleosid
cyclohexenyl
guanin
exhibit
potent
select
activ
vzv
hcmv
wang
et
al
herdewijn
de
clercq
wang
herdewijn
unfortun
due
tediou
synthet
procedur
compound
lead
clinic
candid
howev
serv
increas
understand
aspect
drug
design
biolog
activ
fig
spatial
structur
similar
lobucavir
entecavir
provid
rational
entecavir
uniqu
design
exampl
nucleosid
analogu
featur
sixmemb
ring
instead
typic
fivememb
ring
found
natur
nucleosid
given
potent
activ
exhibit
carbocycl
nucleosid
research
next
turn
replac
furanos
oxygen
atom
see
potenti
impact
biolog
activ
one
replac
includ
isoster
sulfur
atom
yield
thionucleosid
similar
benefit
carbocycl
nucleosid
also
unaffect
glycosid
hydrolas
fig
messini
et
al
elzagheid
et
al
crnugelj
et
al
sulfur
relat
oxygen
sever
way
includ
similar
electron
configur
number
valenc
electron
howev
sulfur
less
electroneg
larger
size
oxygen
contrast
sulfur
particip
hydrogen
bond
like
oxygen
thu
substitut
result
loss
import
interact
enzym
bind
pocket
paulsen
numer
analogu
synthes
secrist
et
al
messini
et
al
elzagheid
et
al
other
paulsen
inou
et
al
crnugelj
et
al
none
led
market
drug
mani
year
later
jeong
et
al
develop
analog
selenonucleosid
howev
none
show
meaning
anticanc
antivir
activ
like
due
lack
recognit
cellular
kinas
phosphoryl
fig
sahu
et
al
yu
et
al
extens
methylen
group
posit
compound
howev
result
potent
activ
ec
valu
low
sinc
analogu
abl
phosphoryl
cellular
kinas
sahu
et
al
yu
et
al
anoth
modif
prove
highli
success
use
nitrogencontain
imino
sugar
found
immucillin
fig
develop
schramm
et
al
kicska
et
al
schramm
tyler
howev
discuss
cnucleosid
section
review
modifi
analogu
azt
ddi
ddc
effect
antivir
analogu
research
concurr
specul
much
sugar
scaffold
could
remov
still
retain
activ
nucleosid
studi
found
could
moieti
remov
could
also
excis
yield
dub
acycl
nucleosid
fig
deval
de
clercq
et
al
sekiyama
et
al
king
elion
kimberlin
freeman
gardin
one
medic
import
acycl
nucleosid
acyclovir
acycl
guanosin
mimic
display
high
specif
activ
toward
fig
king
elion
kimberlin
freeman
gardin
reardon
spector
mcmahon
et
al
high
specif
activ
due
mani
factor
exampl
acyclovir
readili
recogn
phosphoryl
viral
thymidin
kinas
correspond
cellular
thymidin
kinas
king
reardon
spector
rate
fold
higher
thu
lead
higher
concentr
monophosphoryl
acyclovir
infect
cell
oppos
uninfect
cell
elion
mcmahon
et
al
addit
triphosphoryl
acyclovir
recogn
incorpor
fold
effici
viral
dna
polymeras
compar
cellular
polymeras
king
reardon
spector
also
shown
acyclovir
inher
flexibl
allow
optim
interact
target
enzym
bind
site
alvarezro
palafox
tuttl
krenitski
et
al
unfortun
like
nucleosid
analogu
acyclovir
suffer
poor
water
solubl
thu
low
oral
bioavail
de
miranda
blum
elion
et
al
one
way
allevi
issu
add
prodrug
moieti
nucleosid
analogu
increas
comparison
structur
guanosin
acycl
nucleosid
ganciclovir
miss
carbon
correspond
acyclovir
miss
hydroxyl
group
penciclovir
analog
carbocycl
version
ganciclovir
lipophil
ultim
increas
deliveri
activ
analogu
activ
site
case
acyclovir
variou
amino
acid
ester
acyclovir
synthes
includ
valin
ester
prodrug
acyclovir
valacyclovir
serv
increas
oral
bioavail
fold
human
fig
colla
et
al
bra
et
al
weller
et
al
steingrimsdottir
et
al
perri
fauld
soullawton
et
al
smiley
et
al
increas
bioavail
also
result
improv
efficaci
herpesvirus
varicellazost
viru
cytomegaloviru
infect
previous
shown
less
suscept
acyclovir
perri
fauld
soullawton
et
al
smiley
et
al
burnett
et
al
beutner
moreov
valacyclovir
could
administ
form
eye
drop
treat
herpet
kerat
contrast
acyclovir
administ
ointment
maudgal
et
al
increas
absorpt
valacyclovir
attribut
facilit
transport
valacyclovir
across
intestin
membran
human
oligopeptid
transport
compar
simpl
diffus
util
acyclovir
de
vrueh
et
al
baliman
et
al
valacyclovir
also
util
treatment
perri
fauld
smiley
et
al
beutner
initi
discoveri
acyclovir
led
mani
research
pursu
addit
nucleosid
analogu
util
acycl
sugar
scaffold
one
exampl
ganciclovir
also
acycl
guanosin
mimic
howev
unlik
acyclovir
ganciclovir
retain
group
fig
kimberlin
freeman
gardin
hewlett
et
al
fanhavard
et
al
ganciclovir
commonli
use
treat
hcmv
immunocompromis
patient
like
acyclovir
hcmv
infect
cell
higher
affin
ganciclovir
noninfect
cell
kimberlin
fanhavard
et
al
unfortun
sinc
hcmv
treatment
usual
long
term
instanc
resist
ganciclovir
report
kimberlin
hewlett
et
al
komatsu
et
al
like
acyclovir
gancyclovir
also
demonstr
low
bioavail
increas
addit
valin
ester
yield
prodrug
valganciclovir
fig
curran
nobl
martin
et
al
valganciclovir
current
util
treatment
cmv
retin
patient
hiv
well
prophylact
treatment
prevent
cmv
transplant
patient
reischig
et
al
paya
et
al
martin
et
al
piketti
et
al
de
clercq
field
chamberlain
et
al
anoth
exampl
penciclovir
carbocycl
guanosin
analogu
similar
structur
acyclovir
ganciclovir
howev
penciclovir
methylen
group
instead
oxygen
acycl
sugar
moieti
fig
boyd
et
al
boyd
et
al
harnden
jarvest
like
acyclovir
penciclovir
also
potent
therapeut
howev
surprisingli
penciclovir
demonstr
lower
bioavail
acyclovir
thu
research
attempt
find
suitabl
prodrug
de
clercq
field
harnden
jarvest
vere
hodg
et
al
studi
ultim
led
develop
famciclovir
prodrug
analogu
util
typic
acet
prodrug
hydroxyl
moieti
also
featur
remov
carbonyl
group
guanosin
nucleobas
fig
harnden
et
al
enzymat
oxid
vivo
nucleobas
add
carbonyl
purin
ring
hydrolysi
acet
group
famciclovir
yield
penciclovir
vere
harnden
et
al
vere
hodg
due
increas
bioavail
associ
famciclovir
analogu
util
year
treatment
well
herp
zoster
infect
administ
less
frequent
lower
dose
compar
acyclovir
treatment
de
clercq
field
degreef
group
tyre
et
al
sack
et
al
mertz
et
al
dnarna
replic
nucleosid
phosphoryl
variou
host
cell
kinas
activ
triphosph
form
taken
polymeras
incorpor
grow
chain
de
clercq
neyt
deval
process
requir
modifi
nucleosid
howev
one
major
limit
util
nucleosid
drug
specif
kinas
involv
variou
phosphoryl
step
step
becom
rate
limit
overal
convers
activ
triphosph
form
sinc
nucleosid
analogu
alway
recogn
effici
thu
may
initi
appear
inact
becam
import
design
analogu
could
overcom
issu
de
clercq
pertusati
et
al
de
clercq
regard
research
attempt
util
monophosph
analogu
howev
phosphat
group
render
nucleotid
extrem
polar
therefor
make
difficult
compound
cross
cellular
membran
moreov
also
increas
suscept
compound
toward
degrad
cellular
enzym
particularli
phosphatas
thu
viabl
solut
pertusati
et
al
de
clercq
macchi
et
al
late
team
circumv
issu
ad
phosphon
rather
phosphat
group
acycl
nucleosid
scaffold
increas
stabil
phosphat
bond
also
success
deliv
monophosph
mimic
cell
therebi
overcom
first
ratelimit
phosphoryl
step
well
overcom
issu
deliveri
de
clercq
de
clercq
macchi
et
al
rosenberg
correspond
acycl
nucleosid
phosphon
anp
associ
prolong
antivir
activ
due
fact
compound
longer
suscept
cellular
phosphatas
would
cleav
phosphorest
bond
revert
back
parent
nucleosid
de
clercq
pertusati
et
al
macchi
et
al
engel
addit
phosphon
moieti
also
increas
scope
antivir
activ
seen
anp
cidofovir
adefovir
tenofovir
fig
de
clercq
cidofovir
shpmpc
fig
cytosin
deriv
retain
correspond
group
demonstr
activ
dna
virus
includ
polyoma
papilloma
adeno
poxviru
vzv
hcmv
epsteinbarr
viru
de
clercq
de
clercq
lalezari
et
al
primari
use
cidofovir
treatment
hcmv
retin
aid
patient
cidofovir
current
one
licens
antivir
drug
stockpil
possibl
use
short
term
prophylaxi
smallpox
event
biolog
weapon
attack
de
clercq
de
clercq
unfortun
cidofovir
like
almost
acycl
nucleosid
phosphon
associ
sever
side
effect
includ
nephrotox
impair
renal
function
side
effect
due
presenc
phosphon
moieti
thu
cidofovir
contain
black
box
warn
limit
use
short
term
therapi
de
clercq
lalezari
et
al
smee
et
al
anoth
acycl
nucleosid
phosphon
initi
garner
much
attent
adefovir
rpmea
fig
adenosin
analogu
first
util
treatment
hiv
howev
high
dosag
need
associ
toxic
numer
advers
side
effect
de
clercq
de
clercq
hadziyanni
et
al
dando
plosker
angu
et
al
adefovir
still
use
countri
howev
much
lower
dosag
subsequ
proven
effect
inexpens
treatment
chronic
hepat
b
infect
de
clercq
de
clercq
contrast
one
wide
use
phosphon
nucleosid
drug
tenofovir
rpmpa
tenofovir
fig
adenosin
analogu
util
treat
hiv
well
chronic
hepat
b
infect
de
clercq
de
clercq
unfortun
like
acycl
nucleosid
phosphon
tenofovir
associ
low
bioavail
howev
greatli
increas
addit
prodrug
moieti
de
clercq
fung
et
al
porch
chapman
et
al
tenofovir
disoproxyl
fumar
tdf
initi
market
demonstr
higher
potenc
greater
efficaci
parent
tenofovir
fig
fung
et
al
porch
chapman
et
al
recent
howev
tenofovir
alafenamid
taf
larg
replac
tdf
hiv
treatment
primarili
due
signific
differ
dosageonli
mg
vs
mg
well
greatli
increas
level
nucleotid
insid
viral
infect
cell
de
clercq
ray
et
al
recent
fig
exampl
acycl
nucleosid
phosphon
cidofovir
adefovir
tenofovir
phosphat
group
replac
stabl
phosphon
group
fig
structur
acycl
nucleosid
phosphon
tenofovir
prodrug
analogu
tenofovir
disoproxyl
fumar
tenofovir
alafenamid
kl
seleyradtk
mk
yate
antivir
research
grow
concern
increas
incid
nephrotox
renal
issu
relat
tdf
arisen
similar
phosphon
although
side
effect
took
year
aris
rawal
et
al
de
clercq
ray
et
al
birku
et
al
importantli
almost
report
resist
taf
report
therebi
render
taf
much
effect
safe
drug
de
clercq
ray
et
al
stray
et
al
limit
antivir
use
sever
acycl
nucleosid
phosphon
includ
deriv
demonstr
potent
activ
differ
member
trypanosoma
genu
caus
lethal
african
sleep
sick
fig
kaminski
et
al
kaminski
et
al
adenosin
analogu
effect
deriv
especi
enantiom
demonstr
potent
activ
tb
rhodesiens
ec
kaminski
et
al
kaminski
et
al
potent
analogu
still
investig
potenti
therapeut
yet
reach
clinic
trial
concurr
aforement
approach
modifi
sugar
moieti
numer
modif
also
made
purin
pyrimidin
heterocycl
base
nucleosid
analog
variou
interact
involv
recognit
bind
sugar
nucleosid
enzymeligand
recognit
bind
also
involv
mani
differ
type
interact
base
thu
chang
steric
electron
hydrogen
bond
interact
also
significantli
impact
recognit
subsequ
biolog
activ
jordheim
et
al
de
clercq
neyt
deval
modif
heterobas
primarili
focus
ad
substitu
onto
base
remov
ad
atom
ring
chang
posit
atom
type
chang
serv
creat
mani
new
class
nucleosid
analogu
year
although
variou
modif
made
pyrimidin
ring
one
common
earli
modif
nucleosid
drug
design
involv
ad
substitu
posit
pyrimidin
ring
modif
potenti
alter
steric
electron
environ
even
hydrogen
bond
interact
enzym
bind
site
nucleosid
analogu
de
clercq
prusoff
kaufman
heidelberg
whitley
one
earli
nucleosid
util
modif
idoxuridin
analogu
iodin
posit
uridin
ring
fig
de
clercq
prusoff
idoxuridin
one
first
exampl
pyrimidin
analogu
origin
develop
anticanc
agent
howev
subsequ
studi
later
determin
treatment
idoxuridin
also
associ
profound
antivir
activ
notabl
dna
virus
hsv
prusoff
noteworthi
modifi
analogu
develop
earli
includ
trifluridin
primarili
use
ocular
herp
infect
deoxyuridin
brivudin
util
treat
vzv
fig
de
clercq
bauer
kaufman
heidelberg
whitley
de
clercq
et
al
mention
previous
use
fluorin
sugar
nucleosid
known
advantag
also
prove
true
nucleobas
anticanc
drug
correspond
floxuridin
import
exampl
bioisoster
replac
fluorin
hydrogen
fig
seri
biolog
mediat
reaction
first
convert
nucleosid
monophosph
subsequ
becom
part
ternari
complex
thymidyl
synthas
cofactor
longley
et
al
santi
et
al
hydrogen
normal
present
subsequ
abstract
thymidyl
synthas
therebi
caus
complex
disassembl
ultim
lead
thymidin
tetrahydrofol
replac
hydrogen
fluorin
result
deadend
complex
come
apart
therefor
lead
product
thymidin
longley
et
al
santi
et
al
sinc
process
critic
sourc
thymidin
cancer
cell
need
elev
level
thymidin
replic
use
highli
effect
longley
et
al
santi
et
al
notabl
addit
fluorin
posit
also
render
cytosin
nucleosid
stabl
deaminas
enzym
known
inactiv
mani
nucleosid
amin
group
base
highlight
import
particular
structur
modif
secrist
et
al
montgomeri
et
al
park
et
al
anoth
commonli
pursu
modif
posit
involv
addit
variou
alkyl
group
systemat
pursu
systemat
increas
length
alkyl
chain
one
methylen
group
fig
type
homolog
modif
pursu
two
main
reasonson
increas
drug
lipophil
aid
deliveri
two
potenti
increas
fit
drug
hydrophob
pocket
enzym
bind
site
silverman
holladay
dohm
et
al
initi
studi
reveal
increas
chain
length
often
led
increas
activ
certain
point
trend
revers
nucleosid
lost
activ
dohm
et
al
like
due
nucleosid
becom
lipophil
lead
aggreg
accumul
fatti
tissu
silverman
holladay
dohm
et
al
fig
exampl
typic
heterocycl
modif
pyrimidin
moieti
fig
exampl
homolog
seri
modif
increas
lipophil
certain
threshold
modif
help
increas
knowledg
paramet
enzym
bind
site
import
lipophil
analogu
prove
clinic
relev
led
oft
quot
phrase
methyl
ethyl
propyl
butyl
futil
origin
alkyl
modif
led
discoveri
long
chain
substitut
analogu
bicycl
pyrimidin
nucleosid
analogu
bcna
origin
discov
balzarini
mcguigan
fig
balzarini
mcguigan
mcguigan
et
al
structur
activ
relationship
studi
even
potent
bcna
discov
high
specif
toward
vzv
treatment
balzarini
mcguigan
analogu
especi
potent
ec
valu
compar
brivudin
acyclovir
ec
respect
two
analogu
alreadi
use
clinic
treat
vzv
infect
balzarini
mcguigan
analogu
extrem
potent
vzv
also
demonstr
low
cytotox
level
balzarini
mcguigan
mcguigan
et
al
alkyl
studi
increas
branch
bcna
associ
decreas
antivir
activ
optimum
length
prove
mcguigan
et
al
luoni
et
al
mention
earlier
ad
substitu
type
modif
routin
tri
effort
find
activ
temper
side
effect
common
modif
includ
remov
reloc
variou
atom
nucleobas
exampl
remov
nitrogen
purin
pyrimidin
ring
system
refer
deaza
analogu
could
util
explor
effect
hydrogen
bond
interact
enzym
bind
site
given
remov
addit
strong
hydrogen
bond
donor
acceptor
affect
reactiv
well
properti
posit
base
approach
profound
affect
one
import
exampl
replac
ch
fig
mian
khwaja
liu
et
al
modif
result
broad
spectrum
antivir
activ
dna
rna
virus
potent
antitumor
properti
leukemia
cell
line
also
observ
mian
khwaja
revankar
et
al
medic
relev
deaza
analogu
analogu
tubercidin
replac
ch
group
fig
olsen
et
al
ac
et
al
itoh
et
al
tubercidin
origin
isol
bacteria
streptomyc
tubercidicu
demonstr
potent
activ
antibiot
streptococcu
faecali
olsen
et
al
ac
et
al
bloch
et
al
mani
earli
deaza
compound
purin
other
similarli
use
deaza
approach
pyrimidin
analogu
pyrimidin
ring
replac
ch
fig
ebrahimi
et
al
patch
et
al
analogu
display
meaning
biolog
activ
analogu
often
help
identifi
specif
requir
variou
amino
acid
involv
bind
within
enzym
bind
site
patch
et
al
anoth
common
nitrogen
modif
addit
nitrogen
purin
ring
system
refer
aza
analogu
type
modif
introduc
new
hydrogen
bond
donor
acceptor
depend
upon
posit
ring
system
direct
reactiv
aromat
ring
toward
nucleophil
electrophil
substitut
one
exampl
type
modif
present
antibiot
analogu
origin
isol
streptoverticillium
ladakanu
fig
winkley
robin
addit
extra
nitrogen
also
endow
profound
anticanc
properti
specif
acut
myelogen
leukemia
human
breast
cancer
well
treatment
myelodysplast
syndrom
winkley
robin
chang
et
al
gryn
et
al
raj
mufti
nitrogen
remov
ad
pyrimidin
purin
scaffold
nitrogen
also
reposit
ring
thu
retain
number
nitrogen
parent
nucleosid
also
introduc
altern
hydrogen
bond
donor
acceptor
therefor
interact
new
area
enzym
bind
site
especi
true
adenosin
mimic
pyrimidin
fig
due
antiparasit
activ
associ
analogu
numer
research
subsequ
attempt
add
variou
substitu
pyrazol
moieti
order
increas
activ
howev
date
approach
proven
particularli
fruit
petri
et
al
bhat
et
al
montgomeri
et
al
rideout
et
al
sinc
chang
size
sugar
ring
led
clinic
relev
result
nucleosid
analogu
research
also
pursu
increas
size
nucleobas
regard
nelson
leonard
earli
pioneer
develop
base
modifi
nucleosid
first
introduc
nucleosid
field
concept
benzyl
kl
seleyradtk
mk
yate
antivir
research
expand
purin
includ
linbenzoadenosin
well
correspond
proxim
distal
analogu
fig
leonard
et
al
leonard
et
al
leonard
et
al
leonard
analogu
origin
develop
order
probe
adenosin
metabol
enzym
bind
site
determin
upper
limit
enzymesubstr
recognit
leonard
et
al
leonard
numer
studi
determin
modif
serv
increas
aromat
polariz
heterocycl
base
also
increas
stack
import
element
recognit
enzym
bind
site
leonard
et
al
leonard
et
al
lee
kool
lynch
et
al
krueger
et
al
unfortun
compound
demonstr
interest
biolog
activ
none
prove
potent
enough
continu
clinic
mani
year
later
seleyradtk
took
leonard
shape
modif
one
step
replac
leonard
benzen
spacer
ring
variou
fivememb
heteroaromat
ring
notabl
seri
thienoexpand
purin
fig
tricycl
thieno
analogu
associ
numer
benefit
still
retain
essenti
recognit
element
parent
nucleosid
includ
increas
aromat
polariz
base
zhang
et
al
wauchop
et
al
chen
et
al
analogu
also
smaller
leonard
benzyl
spacer
deriv
thu
base
pair
readili
zhang
et
al
wauchop
et
al
shape
modifi
nucleosid
show
interest
biolog
activ
sever
area
includ
hcv
cancer
wallac
et
al
seley
et
al
well
serv
probe
variou
enzym
bind
site
quirk
seley
howev
synthesi
analogu
excess
tediou
plagu
overal
unaccept
low
yield
thu
pursu
extens
sinc
initi
studi
numer
analogu
either
sugar
nucleobas
modif
employ
research
cours
limit
one
two
modif
per
analogu
mani
analogu
featur
multipl
modif
nucleobas
andor
sugar
includ
doubl
modif
posit
sugar
well
glycosid
bond
although
complex
nucleosidetid
analogu
review
extens
second
paper
seri
sever
addit
class
nucleosid
briefli
cover
fall
categori
alreadi
discuss
mention
previous
one
limit
factor
develop
nucleosid
analogu
stabil
glycosid
bond
cleavag
variou
glycosid
hydrolas
research
opt
remov
furanos
oxygen
creat
carbocycl
analogu
overcom
issu
glycosid
bond
instabl
other
attempt
remov
nitrogen
purin
ring
creat
cnucleosid
fig
de
clercq
et
al
temburnikar
seleyradtk
one
first
cnucleosid
discov
pseudouridin
natur
deriv
nucleosid
analogu
pyrimidin
ring
attach
ribos
moieti
instead
fig
de
clercq
et
al
srinivasan
borek
charett
gray
pseudouridin
commonli
found
transfer
rna
ribosom
rna
abund
natur
occur
cnucleosid
et
al
charett
gray
signific
biolog
activ
associ
pseudouridin
discoveri
aid
discoveri
identif
medic
relev
cnucleosid
et
al
one
analogu
showdomycin
natur
occur
uridin
mimic
first
isol
streptomyc
showdonesi
nishimura
et
al
fig
nishimura
et
al
showdomycin
prove
effect
antibiot
sever
gramposit
gramneg
bacteria
particularli
streptococcu
haemolyticu
streptococcu
pyogen
royburman
et
al
darnal
et
al
furthermor
analogu
also
demonstr
potent
antitumor
activ
ehrlich
mous
ascit
well
hela
cell
vitro
et
al
royburman
et
al
darnal
et
al
import
exampl
cnucleosid
includ
aforement
immucillinh
forodesin
fig
warren
fig
exampl
aza
modif
heterobas
scaffold
nitrogen
ad
either
purin
pyrimidin
ring
korycka
et
al
boutureira
et
al
addit
nh
imino
sugar
impart
signific
benefit
correspond
carbocycl
sugar
nitrogen
hydrogen
bond
donor
wherea
furanos
oxygen
simpli
hydrogen
bond
acceptor
thu
expand
potenti
interact
imino
sugar
enzym
bind
site
schramm
tyler
bergeronbrlek
et
al
benefit
especi
seen
immucillinh
transit
state
analogu
inhibit
purin
nucleosid
phosphorylas
pnp
turn
inhibit
growth
malign
cell
human
leukemia
kicska
et
al
korycka
et
al
bantia
et
al
similarli
demonstr
abil
broad
spectrum
antivir
agent
micromolar
activ
numer
virus
includ
ebola
zika
yellow
fever
middl
east
respiratori
syndrom
coronaviru
merscov
name
warren
et
al
juland
et
al
juland
et
al
taylor
et
al
eyer
et
al
nucleosid
featur
alter
glycosid
bond
isonucleosid
also
develop
nelson
leonard
repres
isoadenosin
isoa
wherein
adenin
base
connect
sugar
instead
fig
leonard
laursen
kumar
et
al
leonard
et
al
modif
associ
variou
biolog
activ
notabl
lymphoblast
leukemia
cell
vitro
gerzon
et
al
unfortun
isoa
particularli
stabl
sinc
hyperconjug
tendenc
rearrang
effort
restor
aromat
thu
result
reform
adenosin
seley
et
al
furthermor
isoa
also
unstabl
due
presenc
glycosid
bond
render
analogu
suscept
cleavag
acid
base
glycosid
hydrolas
seley
et
al
led
investig
seleyradtk
et
al
wherein
carbocycl
isoneplanocin
synthes
fig
seley
et
al
analogu
overcam
instabl
glycosid
bond
product
prefer
form
seley
et
al
unfortun
none
analogu
exhibit
clinic
use
level
antivir
anticanc
activ
recent
exampl
isonucleosid
introduc
nair
et
al
featur
glycosid
bond
reloc
sugar
fig
nair
nuesca
nair
jahnk
analogu
prove
exhibit
much
greater
stabil
acid
condit
compar
dideoxi
analogu
halflif
greater
day
ph
compar
halflif
dideoxyadenosin
h
ph
nair
nuesca
nair
jahnk
moreov
analogu
demonstr
potent
micromolar
antihiv
activ
vitro
appar
cytotox
nair
nuesca
nair
jahnk
analogu
possess
potent
activ
hiv
integras
extens
pursu
purpos
nair
jahnk
exampl
modifi
nucleosid
discuss
thu
far
initi
synthes
racem
mixtur
l
fig
comparison
structur
adenosin
correspond
cadenosin
analogu
glycosid
bond
remov
due
remov
nitrogen
purin
ring
nucleosid
howev
becam
appar
gener
one
enantiom
racem
mixtur
respons
activ
addit
also
found
case
lenantiom
could
prove
caus
toxic
interfer
lower
activ
activ
enantiom
although
nt
alway
true
exampl
case
lenantiom
show
differ
activ
even
synergist
activ
inde
l
nucleosid
exhibit
quit
potent
antivir
activ
correspond
nucleosid
particularli
hbv
gumina
et
al
gumina
et
al
notabl
exampl
biolog
relev
l
nucleosid
ftc
identifi
earlier
fig
fig
resolut
two
enantiom
give
lenantiom
dub
prove
quit
import
found
exponenti
activ
hbv
ec
compar
dcounterpart
ec
gumina
et
al
jarvi
fauld
moreov
potent
denantiom
racem
mixtur
also
display
less
toxic
like
due
fact
quit
resist
deamin
gumina
et
al
chang
et
al
potent
activ
hbv
also
make
one
lead
treatment
coinfect
hepat
b
hiv
patient
gumina
et
al
gosselin
anoth
lnucleosid
garner
much
attent
earli
telbivudin
ldt
potent
effect
treatment
chronic
hepat
b
infect
fig
han
kim
et
al
ldt
lenantiom
natur
occur
thymidin
transform
activ
triphosph
form
incorpor
viral
dna
polymeras
induc
chain
termin
han
kim
et
al
comparison
nucleosid
analogu
use
treat
hbv
infect
treatment
ldt
elicit
higher
therapeut
biochem
respons
patient
lai
et
al
lai
et
al
moreov
ldt
specif
hbv
polymeras
recogn
human
polymeras
make
treatment
ldt
safe
effect
kim
et
al
semizarov
et
al
bryant
et
al
anoth
earli
lnucleosid
lfmau
thymidin
analogu
display
potent
antivir
activ
hbv
ec
cell
toxic
report
vitro
fig
du
et
al
initi
hope
lfmau
could
util
treatment
chronic
hbv
infect
howev
ultim
potent
drug
discov
longer
use
clinic
du
et
al
wright
et
al
peek
et
al
anoth
exampl
promis
lnucleosid
featur
lnucleosid
also
util
carbocycl
sugar
scaffold
well
deazapurin
heterobas
fig
seley
et
al
seley
et
al
siddiqi
et
al
initi
studi
found
potent
activ
analogu
sever
pathogen
includ
hbv
four
strain
african
trypanosom
one
known
caus
east
african
sleep
sick
seley
et
al
seley
et
al
final
elvucitabin
cytidin
dideoxynucleosid
revers
transcriptas
inhibitor
also
demonstr
micromolar
activ
hbv
fig
gosselin
bryant
et
al
bryant
et
al
li
et
al
potent
activ
demonstr
analogu
particularli
hbv
led
continu
interest
pursu
lnucleosid
nucleosid
analogu
continu
play
essenti
role
treatment
diseas
thu
pursuit
new
nucleosid
analogu
critic
solv
global
health
issu
emerg
reemerg
infecti
diseas
pathogen
exampl
cover
review
mean
meant
exhaust
would
imposs
show
variou
nucleosid
modif
synthes
broad
categori
howev
intent
provid
flavor
histor
progress
nucleosid
develop
variou
type
structur
modif
pursu
date
field
progress
new
inform
becom
avail
nucleosid
structur
enzym
recognit
biolog
activ
new
complex
modif
pursu
includ
multipl
modif
scaffold
type
approach
review
second
paper
seri
exampl
lenantiom
nucleosid
analogu
assum
inact
sinc
natur
occur
nucleosid
denantiom
later
shown
lnucleosid
exhibit
potent
biolog
activ
varieti
pathogen
